Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
19.64
+0.11 (0.56%)
At close: Dec 5, 2025, 4:00 PM EST
19.80
+0.16 (0.81%)
After-hours: Dec 5, 2025, 7:59 PM EST
TNXP Employees
Tonix Pharmaceuticals Holding had 81 employees as of December 31, 2024. The number of employees decreased by 22 or -21.36% compared to the previous year.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$127,148
Profits / Employee
-$1,224,926
Market Cap
231.29M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TNXP News
- 11 days ago - Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications - Seeking Alpha
- 11 days ago - Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - GlobeNewsWire
- 18 days ago - Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment - GlobeNewsWire
- 21 days ago - Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook - Seeking Alpha
- 25 days ago - Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025 - GlobeNewsWire